Natural orifice spinal surgical approach patent licensing opportunity available.
NovApproach Spine owns patents: US 8,979,861 and US 9,155,633 and patent(s) pending that include method and device claims for spinal surgery intended to:
minimize visible scarring
shorten recovery time
reduce OR time
reduce surgical risks
Natural Orifice Transluminal Endoscopic Surgery (NOTES) "represents one of the most significant innovations in surgery" (Ref. 1)
Robin Young, Orthopedics this Week stated (Ref. 2)
"At a time when many industry veterans are bemoaning the lack of innovation, here comes an unexpected, but entirely reasonable approach, which could certainly drive instrument innovation and create, who knows, a spine procedural revolution comparable to the lateral approaches."
NovApproach Spine also owns the TULIF® spinal approach trademark.
Access to the Intellectual Property may fuel significant market growth for medical device manufacturers while enabling them to achieve their founding mission - to improve patient outcomes.
1 Atallah, S., et al. "Natural‐orifice transluminal endoscopic surgery." British Journal of Surgery 102.2 (2015): e73-e92.
2 "Natural Orifice Spine Procedures", Orthopedics This Week, March 14, 2016
NovApproach Spine, LLC is a technology creation and licensing entity. It does not market medical devices. NovApproach Spine has not received any regulatory clearance to market associated devices and, therefore, does not market any devices for sale in the U.S. or any other country. As a technology creation and licensing entity NovApproach Spine does not practice medicine or provide any medical advice. No multi-center studies have been performed to verify any of the stated or implied claims of the devices and surgical procedure. Therefore, NovApproach Spine does not make any claim or provide any expressed or implied warranty related to the efficacy, safety, risks, complications or potential outcomes of surgeries performed using its intellectual property.